We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability.
- Authors
Feschenko, Elena; Rhodes, David G.; Felberbaum, Rachael; McPherson, Clifton; Riniger, Joseph A.; Post, Penny; Cox, Manon MJ
- Abstract
Background: The recent H1N1 influenza pandemic illustrated the shortcomings of the vaccine manufacturing process. The A/California/07/2009 H1N1 pandemic influenza vaccine or A(H1N1)pdm09 was available late and in short supply as a result of delays in production caused by low yields and poor antigen stability. Recombinanttechnology offers the opportunity to shorten manufacturing time. A trivalent recombinant hemagglutinin (rHA)vaccine candidate for seasonal influenza produced using the baculovirus expression vector system (BEVS) was shown to be as effective and safe as egg-derived trivalent inactivated vaccine (TIV) in human clinical studies. In this study, we describe the characterization of the A/California/07/2009 rHA protein and compare the H1N1 pandemic rHA to other seasonal rHA proteins.Results: Our data show that, like other rHA proteins, purified A/California/07/2009 rHA forms multimeric rosette-like particles of 20–40 nm that are biologically active and immunogenic in mice as assayed by hemagglutinationinhibition (HAI) antibody titers. However, proteolytic digest analysis revealed that A/California/07/2009 rHA is more susceptible to proteolytic degradation than rHA proteins derived from other seasonal influenza viruses. We identified a specific proteolytic site conserved across multiple hemagglutinin (HA) proteins that is likely more accessible in A/California/07/2009 HA, possibly as a result of differences in its protein structure, and may contribute to lower antigen stability.Conclusion: We conclude that, similar to the recombinant seasonal influenza vaccine, recombinant A(H1N1)pdm09vaccine is likely to perform comparably to licensed A(H1N1)pdm09 vaccines and could offer manufacturingadvantages.
- Subjects
INFLUENZA A virus, H1N1 subtype; PANDEMICS; INFLUENZA vaccines; HEMAGGLUTININ; INFLUENZA
- Publication
BMC Biotechnology, 2012, Vol 12, Issue 1, p77
- ISSN
1472-6750
- Publication type
Article
- DOI
10.1186/1472-6750-12-77